Press Materials
Celon Pharma S.A.’s TransformRNA project received co-financing in the competition organized by the Medical Research Agency
The aim of the competition was to support the development of drug technologies based on nucleic acids (RNA and DNA). As one of the most promising trends in modern biotechnology, they may play a crucial role in ensuring national epidemiological safety and preventing infectious diseases.
Doubled export sales, continuation of the strategy of investing in research and development
Net revenue from total sales in the first half of 2021 totalled PLN 105 million. Mostly due to export sales, which exceeded domestic sales. The majority of the Company’s products have maintained their market share in Poland, while the dynamic of the entire drug market in Poland has been decreasing.
Celon Pharma has completed its book – building process. Investors will be taking over all Offered Shares.
Celon Pharma has completed its book – building process. Investors will be taking over all Offered Shares.
Celon Pharma S.A. launches public offering of D-series shares
On 01 July 2021 Celon Pharma S.A. received the decision on approval of the prospectus by the Polish Financial Supervision Authority and published its prospectus in connection with its public offering of D-series shares (the “Offering”). The maximum price in the Offering was set at PLN 45 per share. The Company intends to issue up to 6,000,000 shares and obtain EUR 60 million to finance development of its clinical pipeline and for other corporate purposes, over the course of the next two years.
Celon Pharma Files for Approval of Phase II Trial of CPL’280, a Second Generation GPR40 Agonist, in Type 2 Diabetes.
Celon Pharma today announced filing for approval to start a Phase II clinical study of CPL’280, its second generation GPR40 agonist in type 2 diabetes. This double-blind, randomized, placebo-controlled, multiple dose Phase II study will evaluate the ability of orally administered CPL’280 to control blood glucose in patients with diagnosed type 2 diabetes. Both naiveRead more »
Dynamic export and continuation of positive trends in the development of innovative products
Dynamic export and continuation of positive trends in the development of innovative products
Celon Pharma Announces Successful Completion of Phase 1A Trial of CPL’116, JAK-ROCK Inhibitor.
Celon Pharma S.A. today announced the successful completion of its Phase 1A trial of its JAK/ROCK kinases dual inhibitor, CPL’116. CPL’116 was administered orally in single ascending doses in healthy volunteers in order to assess safety and pharmacokinetic parameters (PK). No adverse events associated with administration of the investigational drug were observed, and the trial metRead more »
Celon Pharma Announces Positive Falkieri Phase II Results in Treatment-Resistant Bipolar Depression
Jan 8, 2020—Celon Pharma ($CLN.PL) today announced positive top-line results from a Phase II study of Falkieri (proprietary esketamine dry powder inhalation) in acute phase of treatment-resistant bipolar depression. View the webcast from TC See the presentation from the Meeting. In the trial, Falkieri met the primary endpoint with statistically significant reductions in MADRS total scoreRead more »